CTi Biopharma CorpCTIC:NAQ

2.55
0.04 / 1.54%
545.67k
135.02%
1.12
Close in USDToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Aug 28 2014 21:00 BST.

Consensus recommendation

As of Aug 22, 2014, the consensus forecast amongst 6 polled investment analysts covering CTI BioPharma Corp advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Nov 04, 2013. The previous consensus forecast advised investors to purchase equity in CTI BioPharma Corp.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy2
Outperform3
Hold1
Underperform0
Sell0
No opinion0

Research Reports

S&P Capital IQ Quantitative Report
Ford Investor Services, Inc.
S&P Capital IQ Quantitative Report

Share price forecast

The 5 analysts offering 12 month price targets for CTI BioPharma Corp have a median target of 4.50, with a high estimate of 6.00 and a low estimate of 4.00. The median estimate represents a 76.47% increase from the last price of 2.55. View Full Financials

High+135.3 %6.00
Med+76.5 %4.50
Low+56.9 %4.00

Dividends

Dividend information is not available for CTi Biopharma Corp. View Full Financials

Earnings history & estimates

On Aug 04, 2014, CTI BioPharma Corp reported 2nd quarter 2014 losses of -0.19 per share. This result under-performed the -0.13 loss expectation of the 3 analysts following the company but exceeded last year's 2nd quarter results by 11.76%. View Full Interim Financials

Average growth rate-6.32%

CTI BioPharma Corp reported annual 2013 losses of -0.43 per share on Mar 04, 2014. View Full Annual Financials

Average growth rate+45.22%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

CTI BioPharma Corp. had 2nd quarter 2014 revenues of 1.34m. This missed the 15.73m consensus estimate of the 3 analysts following the company. This was 4.82% below the prior year's 2nd quarter results. View Full Interim Financials

Average growth rate+57.12%

CTI BioPharma Corp. had revenues for the full year 2013 of 2.31m. View Full Annual Financials

Average growth rate+66.25%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.